Wacker adds half-life boosting tech to biologics offering
Wacker Biotech has added a low cost PEGytlation alternative to its biopharmaceutical manufacturing offering in a deal with developer XL-protein.
Archives for November 5, 2012
Lilly’s in-house trend continues with $140m insulin investment
Eli Lilly plans to boost its in-house insulin production capabilities will a $140m investment for its Indianapolis site.
News from Watson, OvaScience and Sirona – People on the move
in-PharmaTechnologist.com presents its weekly round-up of the latest appointments in the pharmaceutical industry, including news from Watson, OvaScience and Sirona.
Late phase services on rise thanks to need for "real world" data, says ISR
The late phase services industry is growing thanks to a new regulatory need for more “real world” data, says ISR Reports.
Novartis to build biotech facility in Singapore
Novartis will spend $500m on a new cell-culture based manufacturing facility in Singapore.
Is Eli Lilly distancing itself from outsourcing?
Eli Lilly is bringing more production in-house after investing $140m in the expansion of its US insulin site.
Contracts for Cytovance, Patheon and Angel Biotechnology
New contracts for Cytovance, Patheon and Angel Biotechnology in Outsourcing-pharma.com’s roundup of the latest manufacturing deals.
Merck Millipore and Sistemic to use miRNA for cell culture QC
Merck Millipore and microRNA detection firm Sistemic have teamed up to develop QC kits for stem cell production.